Story perspectives

Biotech Resilience: AbbVie and Amgen Post Record Revenues

3/10/2026

Summary

Story summary

Josh Brown and Sean Russo of Ritholtz Wealth Management discuss biotech stocks, noting AbbVie posted 2025 revenues of $61.2 billion driven by Skyrizi and Rinvoq, and Amgen reached $36.8 billion with 18 products at record sales.
Both are in an upward trend, with support at the 50-day and 200-day moving averages.
Investors should monitor these levels for potential entry points and risk management.
The analysis highlights biotech resilience amid market disruptions.

1 of 1

Story summary

Josh Brown and Sean Russo of Ritholtz Wealth Management discuss biotech stocks, noting AbbVie posted 2025 revenues of $61.2 billion driven by Skyrizi and Rinvoq, and Amgen reached $36.8 billion with 18 products at record sales.
Both are in an upward trend, with support at the 50-day and 200-day moving averages.
Investors should monitor these levels for potential entry points and risk management.
The analysis highlights biotech resilience amid market disruptions.